Michelle Mitchell – CEO, Multiple Sclerosis Society, UK
Michelle Mitchell, CEO of the Multiple Sclerosis Society in the UK since 2013, discusses her charity’s aims; their focus on research and development; funding in the face of Brexit; and…
Address: First Floor, Building 2,
Croxley Green Business Park,
Marlins Meadows
Watford, Hertfordshire
United Kingdom – WD18 8YA
Tel: +44 (0) 1923 202 950
Web: http://eu.glenmark-generics.com/
Glenmark Generics (Europe) Ltd headquartered in the UK operates through its own sales infrastructure in the UK and through licensing & distribution arrangements in other European markets.
The UK office based in Hatfield, Hertfordshire possesses the infrastructure to support licensing, regulatory submissions, project management, distribution of sales in the UK and across Europe.
Glenmark is building its presence in markets across Europe and seeks out opportunities to develop strategic alliances and marketing collaborations with leading generic companies operating in the EU markets.
Glenmark was awarded the prestigious SCRIP award in 2008 for the Best Pharma company in the world – SME & the Best Company in Emerging Markets.
Glenmark Generics (Europe) Ltd has an exciting portfolio of 5 approved products, 12 products filed and pending approval; with a further 15 products in development. These are solid and semi-solid products filed as EU CTD dossiers and offered for out-licensing to prospective partners. Most of the portfolio are backed up with vertical integration on APIs.
Michelle Mitchell, CEO of the Multiple Sclerosis Society in the UK since 2013, discusses her charity’s aims; their focus on research and development; funding in the face of Brexit; and…
Recipient of the 2018 Brain Prize for research for groundbreaking research on the generic and molecular basis of Alzheimer’s Disease, the UCL’s Professor John Hardy discusses recent progress in dementia…
Tim de Gavre, country head of Sandoz UK, discusses the role of biosimilars in driving innovation, the threats and opportunities of Brexit to the biosimilars industry, and how Sandoz partners…
Mike Belton of the British Swiss Chamber of Commerce discusses the capabilities of the organization, its role within the British and Swiss investment ecosystem, and how Switzerland can act as…
John Smith, chief executive of the PAGB, the UK’s consumer healthcare industry association, discusses the potential impacts of Brexit on the PAGB’s members, the importance of consumer healthcare to the…
Sarah Haywood, CEO of MedCity, the life science cluster for London, Oxford and Cambridge in the southeast of England, discusses the organization’s strategy, key achievements, Brexit, and supporting SMEs. Why…
In an exclusive interview at the BioPharma Ambition Conference 2016 in Dublin, Sir Andrew Dillon, founding CEO of the UK National Institute for Health and Care Excellence (NICE), shares his…
Lord Philip Hunt, a former UK health minister during the Blair and Brown governments, shares his thoughts on procurement in healthcare, structural change and its impact, and how funds may…
British consultant, speaker and author, Richard Barker – a key opinion leader on UK healthcare – gives his take on the recently launched ‘Life Sciences Industrial Strategy’, the importance of…
Warwick Smith, director general of the British Generic Manufacturers Association (BGMA), discusses the potential impact of Brexit and recent policy changes on the British generics industry and extols the benefits…
Simon Gillespie of the British Heart Foundation (BHF), the UK’s leading national heart charity, outlines the organization’s mission, the issues surrounding translational research, and the potential impact of Brexit on…
Hilary Evans of Alzheimer’s Research UK (ARUK), the UK’s leading national research charity in the field of dementia, discusses her organization’s mission; the growing awareness of, and investment in, dementia…
See our Cookie Privacy Policy Here
